항생제 내성 시장 : 질환별, 병원체별, 약제 클래스별, 작용기서별, 유통 채널별, 세계 예측(2023-2032년)

The antibiotic resistance market will grow with 5.3% CAGR from 2023 to 2032. The development of drug-resistant bacteria triggered by misuse of antibiotic medications is increasing the demand for alternative treatment options, propelling industry expansion.

Additionally, the aging global population, with a higher susceptibility to infections, is driving the need for novel antibiotics. Rising healthcare-associated infections and the emergence of multi-drug-resistant pathogens have also fueled investments in research and development of new antimicrobial agents to combat antibiotic resistance.

Government initiatives, regulatory incentives, and increased awareness about the threat of antibiotic resistance will further contribute to market expansion. In November 2022, the UN's FAO, UNEP, the World Organization for Animal Health, and the WHO announced a new initiative called the Antimicrobial Resistance Multi-Stakeholder Partnership Platform to address the escalating implications of antimicrobial resistance on the global population. Given the pressing need for innovative solutions, the antibiotic resistance industry will expand significantly in the coming years.

The market is segregated based on disease, pathogen, drug class, mechanism of action, distribution channel, and region.

Based on disease, the bloodstream infection segment will exhibit a 5% CAGR from 2023 to 2032. The increasing prevalence of sepsis and bloodstream infections, rising healthcare-associated cases, and the growing challenge of antibiotic-resistant pathogens in critical care settings will drive growth in the segment.

The P. aeruginosa pathogen segment will reflect a 6.5% CAGR through 2032, driven by factors such as the pathogen's widespread resistance to multiple antibiotics, which is driving the demand for alternative treatments. The rising incidences of P. aeruginosa infections in healthcare settings will also foster growth in the segment.

The cephalosporin drug class segment will exhibit 6.1% CAGR between 2023 and 2032, driven by the escalating prevalence of cephalosporin-resistant bacterial strains, which will necessitate the development of new and effective treatments. The rising burden of healthcare-associated infections and demand for innovative antimicrobial agents will also augment growth in the segment.

Regionally, the Asia Pacific antibiotic resistance industry will witness a 5.8% CAGR through 2032, driven by factors such as increasing healthcare access, population density, and antimicrobial misuse in the region. Rising awareness, government initiatives, and economic development will further drive industry expansion as the region addresses antibiotic resistance challenges.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 Covid-19 impact analysis at global level
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Secondary
    • 1.6.1.1 Paid sources
    • 1.6.1.2 Public sources
  • 1.6.2 Primary

Chapter 2 Executive Summary

• 2.1 Antibiotic resistance industry 360 degree synopsis, 2018 - 2032 (USD Million)
  • 2.1.1 Business trends
  • 2.1.2 Region trends
  • 2.1.3 Disease trends
  • 2.1.4 Pathogen trends
  • 2.1.5 Drug class trends
  • 2.1.6 Mechanism of action trends
  • 2.1.7 Distribution channel trends

Chapter 3 Antibiotic Resistance Market Insights

• 3.1 Industry landscape, 2018 - 2032 (USD Million)
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of antibiotic resistant infections
    • 3.2.1.2 Growing need for new antibiotic therapies
    • 3.2.1.3 Increasing investment for research and development of novel antibiotics
    • 3.2.1.4 Increasing global public health concern and awareness
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of therapeutics
    • 3.2.2.2 Complex regulatory and development process
• 3.3 Growth potential analysis
  • 3.3.1 By disease
  • 3.3.2 By pathogen
  • 3.3.3 By drug class
  • 3.3.4 By mechanism of action
  • 3.3.5 By distribution channel
• 3.4 COVID-19 impact analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Competitive positioning matrix, 2022
• 4.4 Strategic dashboard, 2022

Chapter 5 Antibiotic Resistance Market Estimates and Forecast, By Disease (USD Million)

• 5.1 Key trends, by disease
• 5.2 Complicated urinary tract infections
• 5.3 Complicated intra-abdominal infections
• 5.4 Bloodstream infection
• 5.5 Acute bacterial skin and skin-structure infection
• 5.6 Community-acquired bacterial pneumonia
• 5.7 Clostridium difficile infections
• 5.8 Hospital-acquired bacterial pneumonia

Chapter 6 Antibiotic Resistance Market Estimates and Forecast, By Pathogen (USD Million)

• 6.1 Key trends, by pathogen
• 6.2 E. coli
• 6.3 K. pneumoniae
• 6.4 P. aeruginosa
• 6.5 S. aureus
• 6.6 Baumannii
• 6.7 S. pneumoniae
• 6.8 H. influenzae
• 6.9 C. difficile
• 6.10 E. faecium

Chapter 7 Antibiotic Resistance Market Estimates and Forecast, By Drug Class (USD Million)

• 7.1 Key trends, by drug class
• 7.2 Oxazolidinones
• 7.3 Cephalosporin
• 7.4 Lipoglycopeptides
• 7.5 Combination therapies
• 7.6 Tetracyclines
• 7.7 Other drug classes

Chapter 8 Antibiotic Resistance Market Estimates and Forecast, By Mechanism of Action (USD Million)

• 8.1 Key trends, by mechanism of action
• 8.2 Cell wall synthesis inhibitors
• 8.3 Protein synthesis inhibitors
• 8.4 DNA synthesis inhibitors
• 8.5 RNA synthesis inhibitors
• 8.6 Other mechanism of actions

Chapter 9 Antibiotic Resistance Market Estimates and Forecast, By Distribution Channel (USD Million)

• 9.1 Key trends, by distribution channel
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Antibiotic Resistance Market Estimates and Forecast, By Region (USD Million)

• 10.1 Key trends, by region
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Switzerland
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East & Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East & Africa

Chapter 11 Company Profiles

• 11.1 ACHAOGEN, INC.
• 11.2 Basilea Pharmaceutica Ltd.
• 11.3 MELINTA THERAPEUTICS
• 11.4 Tetraphase Pharmaceuticals, Inc.
• 11.5 Theravance Biopharma
• 11.6 WOCKHARDT
• 11.7 Entasis therapeutics
• 11.8 Paratek Pharmaceuticals, Inc.
• 11.9 Seres Therapeutics
• 11.10 AbbVie, Inc.
• 11.11 Merck & Co. Inc.
• 11.12 Pfizer Inc.